Global Partners (GLP)
(Delayed Data from NYSE)
$40.06 USD
-1.21 (-2.93%)
Updated Jul 19, 2024 04:00 PM ET
3-Hold of 5 3
A Value F Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GLP 40.06 -1.21(-2.93%)
Will GLP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GLP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLP
What Will Global Partners' (GLP) Q1 Earnings Unveil?
Global Partners LP (GLP) Rises As Market Takes a Dip: Key Facts
GLP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Global Partners LP (GLP) Rises As Market Takes a Dip: Key Facts
Matador (MTDR) Q1 Earnings Beat Estimates on Production Volume
Baker Hughes (BKR) Q1 Earnings and Revenues Beat Estimates
Other News for GLP
Global Partners' Series B Preferred Shares Cross 9% Yield Mark
Global Partners Stock Getting Very Oversold
Notable Two Hundred Day Moving Average Cross - GLP
Global Partners Announces Cash Distribution on Series B Preferred Units
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More